Factor Information
Data ID 1347
Factor Volumn of transfusions
Description The mean volume of transfusion for patients was significantly less in the HTK group (760.67± 83.28 vs 1520.00±174.83 mL, P=0.000; Table 4).
Biomarker NA
Classification A12 (clinical factor - treatment)
Association
Application treatment and prognosis
Objective The purpose of this study was to compare myocardial protection of HTK and St. Thomas’ crystalloid cardioplegic solution in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease.
p Value <0.001
Conclusion HTK solution seems to be an effective and safe alternative to St. Thomas’ solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.
Risk Factor unknown
CHD Type
ID 521
CHD Type isolated CHD
CHD Subtype D-TGA/VSD/CHD with PAH
Reference
PMID 27191607
Year 2016
Title Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.
Sample
Population Infants
Source Data
Region Beijing, China
Method Univariate and multivariate analysis
Race Asian
Disease History N/A
Treatment History arterial switch operation
Group histidine-tryptophan-ketoglutarate (HTK) group: myocardial protection was carried out with one single perfusion of HTK solution(Treatment) St group: control group, myocardial protection with conventional St. Thomas’ cold potassium crystalloid cardioplegic solution(Control)
Number 75 26
Age 3.4±0.4 years 1.9±0.4 years
Gender (Male: Female) 38:37 16:10
Marker Level 760.67± 83.28 ml [histidine-tryptophan-ketoglutarate (HTK) group: myocardial protection was carried out with one single perfusion of HTK solution] 1520.00±174.83 mL (St group: control group, myocardial protection with conventional St. Thomas’ cold potassium crystalloid cardioplegic solution)